Billing and Coding: Hyaluronic Acid Injections for Knee Osteoarthritis

Billing for intra‑articular hyaluronic acid injections to treat knee osteoarthritis is allowed only when clinical criteria in LCD L39260 are met and administration follows FDA‑approved dosing. Claims must use specific modifiers (EJ for subsequent injections, JW/JZ for discarded/no-discarded single‑use vials) and appropriate CPT (20610/20611) and site modifiers; series may be repeated after ≥6 months if LCD criteria are satisfied.

"Intra-articular hyaluronic acid (viscosupplementation) injections are billable for treatment of knee osteoarthritis only when the service meets the Local Coverage Determination L39260 clinical crit..."

Sign up to see full coverage criteria, indications, and limitations.